Inovio threw its hat in the coronavirus vaccine ring as early as January 2020. The company claimed to have designed its vaccine, INO-4800, in a mere three hours after Chinese researchers publicly released the genetic sequence of the SARS-CoV-2 virus that causes the disease. Two of the most important missteps in the company's COVID-19 vaccine hunt were as follows.
Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO)Q1 2021 Earnings CallMay 10, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the Inovio Pharmaceuticals first-quarter 2021 financial results conference call.
Inovio (INO) delivered earnings and revenue surprises of -50.00% and -44.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?